Monday, 20 September 2021

LIVE Video

The need to design & manufacture medical technologies indigenously
Videos

Inside Magazine
 
GUNG-HO PHARMA R&D INVESTMENTS SURPASS $3B
 
While the pharmaceutical industry helped combat COVID-19, from R&D actions on potential treatment strategies to balancing the medicines supply chain in the time of crisis, it struggled to maintain the natural market flow. As a result, many pharma companies had to abort some of their ongoing R&D investment plans. However for FY20-21, the average R&D expenses constituted 7.2 per cent of the total revenues of the pharma companies, with Lupin, Alembic Pharma and Dr. Reddy’s spending more than others. 
The cumulative R&D expenditure of the leading 10 pharma companies has been around Rs 10,627 crore ($1.43 billion) in the previous fiscal. This figure eventually reaches an approximate amount of Rs 22,500 crore ($3.03 billion) after considering the cumulative expenditure by other small and medium players of the India pharma industry
 
.
For Feedback, please email us at : communications@mmactiv.com
--

Sign up here to access BioSpectrum India Flip Book.

BioSpectrum Infomercial